Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy

Journal of Clinical Gastroenterology

Volumn 49, Issue 1, 2015, Pages 34-40

  Castaño Milla, Carlos ^a,b   Chaparro, María ^a,b   Saro, Cristina ^b   De Acosta, Manuel Barreiro ^c   García Albert, Ana M ^d   Bujanda, Luis ^e,f   Martín Arranz, María D ^g   Carpio, Daniel ^h   Muñoz, Fernando ⁱ   Manceñido, Noemí ^j   García Planella, Esther ^b   Piqueras, Marta ^k   Calvet, Xavier ^l,m   Cabriada, José L ⁿ   Botella, Belén ^o   Bermejo, Fernando ^b   Gisbert, Javier P ^a,b  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^e HOSPITAL INFANTA CRISTINA   (Spain)

^f HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^g Instituto de Salud Carlos III   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j HOSPITAL DE GALDAKAO   (Spain)

^k HOSPITAL MONTECELO   (Spain)

^l HOSPITAL DE LEÓN   (Spain)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^o Brain   (Spain)

more..

Author keywords

Adalimumab; Crohn's disease; Magnetic resonance imaging; Perianal fistula; Remission

Indexed keywords

ADALIMUMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DERMATITIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GINGIVITIS; HUMAN; LUPUS LIKE SYNDROME; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84988937924     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000169     Document Type: Article

References (37)

1. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
2. ten Cate Hoedemaker HO. Perianal Crohn's disease. Neth J Med. 1994;45:72-75.
3. Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn's fistulas. Aliment Pharmacol Ther. 2011;33:5-22.
4. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
5. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001;135:906-918.
6. Taxonera C, Schwartz DA, Garcia-Olmo D. Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol. 2009;15:4263-4272.
7. Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn's disease. Br J Surg. 1981;68:525-527.
8. Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn's disease: classification and clinical evaluation. Dig Liver Dis. 2007;39:959-962.
9. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther. 2003;17:1145-1151.
10. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(suppl 1):i36-i58.
11. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
13. Uchino M, Ikeuchi H, Bando T, et al. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J Gastroenterol. 2011;17:1174-1179.
14. Higashi D, Futami K, Egawa Y, et al. Infliximab treatment for anal fistula in patients with Crohn's disease. Anticancer Res. 2009;29:927-933.
15. McNamara DA, Brophy S, Hyland JM. Perianal Crohn's disease and infliximab therapy. Surgeon. 2004;2:258-263.
16. Ardizzone S, Maconi G, Colombo E, et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91-96.
17. Poupardin C, Lemann M, Gendre JP, et al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol. 2006;30:247-252.
18. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
19. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
20. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology. 2001;121:1064-1072.
21. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
22. American Gastroenterology Association (AGA). American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology. 2003;125:1503-1507.
23. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125:1508-1530.
24. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009;104:2973-2986.
25. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
26. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
27. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
28. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
29. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58:940-948.
30. Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23:1127-1136.
31. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98-103.
32. Hyder SA, Travis SP, Jewell DP, et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837-1841.
33. Sciaudone G, Di Stazio C, Limongelli P, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg. 2010;53:299-304.
34. Tambasco R, Gionchetti P, Laureti S, et al. Adalimumab in the treatment of perianal Crohn's disease: long-term results in a single tertiary center. J Crohns Colitis. 2012:S153.
35. Savoye-Collet C, Savoye G, Koning E, et al. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis. 2011;17:1751-1758.
36. Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol. 2011;9:130-136.
37. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009;15:1308-1319.